3
Announcements
Trials
Browse
Landscape
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Observational
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
76
Neoplasms
16
Prostatic Neoplasms, Castration-Resistant
14
Neoplasm Metastasis
9
Breast Neoplasms
9
Metastatic Castration Resistant Prostate Cancer
8
Prostate Cancer Metastatic
5
Metastatic Castration-Resistant Prostate Cancer
5
Colorectal Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Small Cell Lung Carcinoma
3
Metastatic Castration-resistant Prostate Cancer
3
Melanoma
3
Bulbo-Spinal Atrophy, X-Linked
3
mCRPC
2
Recurrence
2
Pancreatic Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Metastatic Castrate-Resistant Prostate Cancer
2
Carcinoma, Renal Cell
2
Carcinoma, Hepatocellular
2
Bites and Stings
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumours
1
Seizures
1
Interventions
darolutamide
4
enzalutamide
2
apalutamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
INDUSTRY
×
Non-metastatic Castration-resistant Prostate Cancer
×
enzalutamide
×
Clear all
NCT06013475
2025-06-12
DEAR-EXT
Bayer
Completed
1,375 enrolled
NCT05362149
2024-03-20
DEAR
Bayer
Completed
870 enrolled